Development of Precision method for Pandu

Phase 2/3

Completed

Conditions: Other general symptoms and signs. Ayurveda Condition: PANDUROGAH,

Registration Number: CTRI/2023/08/056119

Lead Sponsor: Government Ayurved Hospital Vadodara

Brief Summary: Clinical study has obtained Institutional Ethics committee clearance (GAC/VAD/IEC/77/2023, Date-24/01/2023) and registered at Clinical Trial Registry of India, ICMR, New Delhi, vide CTRI/2023/08/056119, [Registered on 04/08/2023]. Study type was open labelled clinical trial. 47 patients were enrolled and divided into four groups (i.e., Group A1-A2 â€“ *Vataja Pandu*, Group B1-B2 â€“ *Kaphaja Pandu)* 10 patients in each group were allocated. Total 40 patients (i.e., 10 patients in group A1, 10 patients in Group A2, 10 patients in group B1, 10 patients in Group B2) were completed the study. All individual four groups A1, A2, B1 and B2 were having significant difference percentage in *Pandu.* While, non-significant difference observed between A1-A2 and B1-B2 groups. In overall effect of therapy moderate and mild improvement observed in Group A1 40% and 60%. In Group A2 moderate and mild improvement observed 70% and 39%. Moderate, mild and no improvement observed in Group B1 10%, 60% and 30%. In Group B2 marked, moderate and mild improvement observed 20%, 20% and 60%.

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: All

Target Recruitment: 10

Inclusion Criteria

symptoms of Pandu: Panduta(Paleness) Hridaspandana(Palpitation), Daurbalya(Weakness) Group A: Vata dominant symptoms Pindikodwestana (cramps in the calf muscle), Rukshata (Dryness of skin), Angamarda (Body ache), Kampa (Trembling) Group B: Kapha dominant symptoms Gaurava (Heaviness), Bhrama (Vertigo), Klama (Mental fatigue), Aalasya (Laziness), Aruchi (Anorexia).

Exclusion Criteria

1.Age <20 to > 30 years 2.Uncontrolled clinical conditions like HTN, cancer, HIV, HBsAg, Liver cirrhosis, Cardiac failure, Stroke, etc.
3.History of Metabolic disorder 4.Anemia with any associated severe complication.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Daurbalya(Weakness)	3 week

Secondary Outcome Measures

Name	Time	Method
Hridaspandana(Palpitation),	Panduta(Paleness),Angamarda

Trial Locations

Locations (1): Government Ayurved Hospital, Vadodara
🇮🇳
Vadodara, GUJARAT, India
Government Ayurved Hospital, Vadodara
🇮🇳Vadodara, GUJARAT, India
Urviben Gajanandbhai Pandya
Principal investigator
7069059078
ugpandya1737@gmail.com